8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 19, 2026·SEC
Zura Bio Limited(ZURA)Earnings, Financials & Key Ratios
ZURA•NASDAQ
Price updated Jun 19, 2026
AboutZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$75M-36.3%
- Net Income-$69M-31.0%
- EPS (Diluted)-1.06-76.7%
- ROE-52.49%-20.0%
ZURA Key Insights
Zura Bio Limited (ZURA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Shares diluted 25.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ZURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZURA Price & Volume
Zura Bio Limited (ZURA) stock price & volume — 10-year historical chart
Loading chart...
ZURA Growth Metrics
Zura Bio Limited (ZURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-31.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-29.76%
Return on Capital
10 Years-64.45%
5 Years-64.45%
3 Years-93.3%
Last Year-57.54%
ZURA Recent Earnings
Zura Bio Limited (ZURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.22-29.4%
$0.17
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.49-172.2%
$0.18
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.21-10.5%
$0.19
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.17+10.5%
$0.19
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.22vs $0.17-29.4% | — |
| Q2 2026 | Mar 19, 2026 | $0.49vs $0.18-172.2% | — |
| Q4 2025 | Nov 13, 2025 | $0.21vs $0.19-10.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.17vs $0.19+10.5% | — |
Based on last 12 quarters of dataView full earnings history →
ZURA Peer Comparison
Zura Bio Limited (ZURA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare ZURA vs Peers
Zura Bio Limited (ZURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZURA Income Statement
Zura Bio Limited (ZURA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 16K |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -16K▲ 0% |
Gross Margin % | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 1.09M | 27.16M | 62.64M | 55.19M | 75.25M | 81.49M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 1.09M | 3.47M | 18.64M | 30.79M | 33.16M | 35.14M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 0 | 23.69M | 44M | 24.4M | 42.08M | 46.35M |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -1.09M▲ 0% | -27.16M▼ 2387.4% | -62.64M▼ 130.6% | -55.19M▲ 11.9% | -75.25M▼ 36.3% | -81.49M▲ 0% |
Operating Margin % | - | - | - | - | - | - |
Operating Income Growth % | - | -2387.39% | -130.61% | 11.89% | -36.34% | - |
EBITDA | 8.42M | -27.16M | -62.64M | -55.18M | -75.2M | -81.44M |
EBITDA Margin % | - | - | - | - | - | - |
EBITDA Growth % | - | -422.72% | -130.61% | 11.91% | -36.28% | -23.3% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 9K | 49K | 56K |
EBIT | 8.42M | -27.16M | -62.64M | -55.19M | -75.25M | -81.49M |
Net Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M | 5.84M |
Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M | 5.84M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 9.51M | -171K | 2.08M | 2.79M | 6.6M | 6.06M |
Pretax Income | 8.42M▲ 0% | -27.33M▼ 424.7% | -60.56M▼ 121.6% | -52.4M▲ 13.5% | -68.65M▼ 31.0% | -75.43M▲ 0% |
Pretax Margin % | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | 8.42M▲ 0% | -25.74M▼ 405.8% | -60.36M▼ 134.5% | -52.4M▲ 13.2% | -68.65M▼ 31.0% | -75.43M▲ 0% |
Net Margin % | - | - | - | - | - | - |
Net Income Growth % | - | -405.8% | -134.52% | 13.18% | -31% | -31.14% |
Net Income (Continuing) | 8.42M | -27.33M | -60.56M | -52.4M | -68.65M | -75.43M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 10M | 20.22M | 13.2M | 0 | 0 |
EPS (Diluted) | 0.40▲ 0% | 0.21▼ 47.5% | -2.09▼ 1095.2% | -0.60▲ 71.3% | -1.06▼ 76.7% | -0.67▲ 0% |
EPS Growth % | - | -47.5% | -1095.24% | 71.29% | -76.67% | -29.76% |
EPS (Basic) | 0.40 | 0.21 | -2.09 | -0.60 | -1.06 | - |
Diluted Shares Outstanding | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M | 112.22M |
Basic Shares Outstanding | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M | 112.22M |
Dividend Payout Ratio | - | - | - | - | - | - |
ZURA Balance Sheet
Zura Bio Limited (ZURA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 1.15M | 1.78M | 100.84M | 178.74M | 112.31M | 227M |
Cash & Short-Term Investments | 729.22K | 1.57M | 99.81M | 176.5M | 109.41M | 225.59M |
Cash Only | 729.22K | 1.57M | 99.81M | 176.5M | 109.41M | 225.59M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 189.3K | 1.04M | 2.25M | 2.9M | 1.41M |
Total Non-Current Assets | 139.4M | 3.49M | 0 | 789K | 1.64M | 1.64M |
Property, Plant & Equipment | 0 | 0 | 0 | 91K | 126K | 125K |
Fixed Asset Turnover | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 139.4M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 3.49M | 0 | 698K | 1.51M | 1.51M |
Total Assets | 140.55M▲ 0% | 5.26M▼ 96.3% | 100.84M▲ 1816.4% | 179.53M▲ 78.0% | 113.95M▼ 36.5% | 228.64M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x |
Asset Growth % | - | -96.26% | 1816.44% | 78.03% | -36.53% | -44.58% |
Total Current Liabilities | 272.29K | 14.82M | 20.3M | 19.51M | 12.41M | 11.74M |
Accounts Payable | 0 | 2.01M | 2.75M | 733K | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | 32.84K |
Short-Term Debt | 0 | 7.76M | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 272.29K | 2.77M | 1.2M | 18.78M | 12.41M | 11.74M |
Current Ratio | 4.23x | 0.12x | 4.97x | 9.16x | 9.05x | 19.33x |
Quick Ratio | 4.23x | 0.12x | 4.97x | 9.16x | 9.05x | 19.33x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 10.08M | 12.5M | 990K | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.08M | 12.5M | 990K | 0 | 0 | 0 |
Total Liabilities | 10.35M | 27.32M | 21.29M | 19.51M | 12.41M | 11.74M |
Total Debt | 0 | 7.76M | 0 | 0 | 0 | 0 |
Net Debt | -729.22K | 6.19M | -99.81M | -176.5M | -109.41M | -225.59M |
Debt / Equity | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | -0.09x | - | - | - | - | 2.77x |
Interest Coverage | - | - | - | - | - | - |
Total Equity | 130.2M▲ 0% | -22.06M▼ 116.9% | 79.55M▲ 460.7% | 160.02M▲ 101.2% | 101.54M▼ 36.5% | 216.9M▲ 0% |
Equity Growth % | - | -116.94% | 460.68% | 101.15% | -36.55% | -43.11% |
Book Value per Share | 7.55 | -1.28 | 2.41 | 2.13 | 1.08 | 1.93 |
Total Shareholders' Equity | 130.2M | -32.06M | 59.33M | 146.81M | 101.54M | 216.9M |
Common Stock | 139.38M | 0 | 4K | 7K | 7K | 9K |
Retained Earnings | -9.18M | -32.06M | -103.49M | -155.9M | -224.55M | -248.77M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 10M | 20.22M | 13.2M | 0 | 0 |
ZURA Cash Flow Statement
Zura Bio Limited (ZURA) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -1.1M | -1.2M | -15.05M | -28.08M | -64.81M | -72.67M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | -9.46% | -1152.41% | -86.5% | -130.86% | -492.32% |
Net Income | 8.42M | -27.33M | -60.56M | -52.4M | -68.65M | -75.43M |
Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K | 56K |
Stock-Based Compensation | 0 | 334K | 9.65M | 16.8M | 12.33M | 11.32M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -9.28M | 22.26M | 30.74M | 5.21M | -4.91M | -555K |
Working Capital Changes | -235.6K | 3.54M | 5.12M | 2.31M | -3.63M | -6.07M |
Change in Receivables | 2.87K | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 288.29K | 0 | 4.21M | -2.16M | -4.96M |
Cash from Investing | -139.38M | -12M | -8M | -5.08M | -113K | -77K |
Capital Expenditures | 0 | -12M | -8M | -75K | -113K | -77K |
CapEx % of Revenue | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -5M | 0 | 0 |
Cash from Financing | 141.21M | 14.77M | 121.29M | 109.84M | -2.16M | 127.78M |
Debt Issued (Net) | -117.38K | 7.6M | -10M | 0 | 0 | -90K |
Equity Issued (Net) | 140.82M | 10M | 116.41M | 60.76M | 5.2M | 135.23M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 505K | -2.83M | 14.89M | 49.09M | -7.37M | -7.37M |
Net Change in Cash | 729.22K▲ 0% | 1.57M▲ 114.9% | 98.24M▲ 6169.2% | 76.69M▼ 21.9% | -67.09M▼ 187.5% | 55.02M▲ 0% |
Free Cash Flow | -1.1M▲ 0% | -13.2M▼ 1102.2% | -23.05M▼ 74.6% | -28.15M▼ 22.1% | -64.93M▼ 130.6% | -72.75M▲ 0% |
FCF Margin % | - | - | - | - | - | - |
FCF Growth % | - | -1102.2% | -74.63% | -22.11% | -130.64% | -112.27% |
FCF per Share | -0.06 | -0.77 | -0.70 | -0.37 | -0.69 | -0.65 |
FCF Conversion (FCF/Net Income) | -0.13x | 0.05x | 0.25x | 0.54x | 0.94x | 0.96x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ZURA Key Ratios
Zura Bio Limited (ZURA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | -47.6% | -209.97% | -43.75% | -52.49% | -52.38% |
Return on Invested Capital (ROIC) | -35.86% | - | - | - | 465.48% |
Debt / Equity | - | - | - | - | 0.00x |
FCF Conversion | 0.05x | 0.25x | 0.54x | 0.94x | 0.96x |
Related:ZURA Dividend History·ZURA Revenue History·ZURA Price History·ZURA P/E History·ZURA Financial Ratios·ZURA Institutional Holders
ZURA SEC Filings & Documents
Zura Bio Limited (ZURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZURA Frequently Asked Questions
Zura Bio Limited (ZURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zura Bio Limited (ZURA) grew revenue by 0.0% over the past year. Growth has been modest.
Zura Bio Limited (ZURA) reported a net loss of $75.4M for fiscal year 2025.
Dividend & Returns
Zura Bio Limited (ZURA) has a return on equity (ROE) of -52.5%. Negative ROE indicates the company is unprofitable.
Zura Bio Limited (ZURA) had negative free cash flow of $72.8M in fiscal year 2025, likely due to heavy capital investments.